User Reviews
More
User comment
0
CommentsWrite a review
No comment yet
Score
Japan
5-10 yearsSuspicious Regulatory License
High potential risk
Influence
Add brokers
Comparison
Expose
Exposure
Score
Regulatory Index0.00
Business Index7.23
Risk Management Index0.00
Software Index4.00
License Index0.00
Single Core
1G
40G
Aizawa Review Summary | |
Company Name | Aizawa Securities Co.,Ltd. |
Founded | 2021 |
Registered Country/Region | Japan |
Regulation | Suspicious Clone (FSA) |
Products & Services | Asian Stocks, Asset Management (Include Solution Service) |
Customer Support | Tel: 81(3) 6852-7700, Twitter, YouTube |
Company Address | Tokyo Shiodome Building, 1-9-1 Higashi-Shimbashi, Minato-ku, Tokyo 105-7307 Japan |
Aizawa Securities was established in 1918. Based in Japan, it operates as a securities firm with a focus on Asian stocks. Its regulatory license is flagged as a suspicious clone by the Financial Services Agency (FSA). Aizawa has a long history and significant presence in the Asian stock markets.
Pros | Cons |
|
|
|
Stocks in Various Regions Supported: Aizawa offers access to stocks in various regions including Hong Kong, Shanghai, Shenzhen, South Korea, Taiwan, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, and Israel.
Limited Customer Support: Aizawa's customer support is limited, primarily relying on telephone communication without email or any other form of support.
Suspicious Clone Regulation: Aizawa's regulatory status as a “Suspicious Clone” concerns users about its legitimacy.
Regulatory Sight: Aizawa Securities Co., Ltd. is currently regulated by the Financial Services Agency (FSA), but with a “Suspicious Clone” status. It holds a retail forex license. The license number is 5010001036574.
User Feedback: Users should check the reviews and feedback from other clients to gain a more comprehensive sight of the broker, or look for reviews on reputable websites and forums.
Security Measures: So far we haven't found any information about the security measures for this broker.
Asian Stocks: Clients can trade stocks listed in markets of Hong Kong, Shanghai, Shenzhen, South Korea, Taiwan, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, and Israel. They offer a wide selection of stocks and have extensive experience in handling Asian equities.
Asset Management: Aizawa provides asset management services, assisting clients in managing their investment portfolios, which offers solution services like Inheritance & Business Support.
Aizawa provides customer support primarily through telephone (813 6852-7700). However, the support options are somewhat limited, as there is no provision for email or live chat support for users to submit detailed problem reports or inquiries. Additionally, Aizawa maintains a presence on social media platforms such as YouTube (https://www.youtube.com/channel/UCag2D4NtMd7U3zWoE8ZktYA) and Twitter (https://twitter.com/aizawa1918), where they share educational videos and updates.
Question: Is Aizawa regulated or not?
Answer: Yes, it is regulated by the Financial Services Agency (FSA). However, the regulation is suspected to be a clone.
Question: Does Aizawa provide any guidance on its official website?
Answer: No, there is no guidance on the website. But you can find videos helpful on their YouTube channel.
Question: Is Aizawa a good choice for beginners?
Answer: No. Its regulation is suspicious and the customer service provided is kind of limited. Beginners should try normally regulated securities that provide comprehensive and immediate customer service.
Question: Do they support trading on US stocks?
Answer: No. They support only Asian stocks.
Online trading involves significant risk, and you may lose all of your invested capital. It is not suitable for all traders or investors. Please ensure that you understand the risks involved and note that the information provided in this review may be subject to change due to the constant updating of the company's services and policies.
More
User comment
0
CommentsWrite a review
No comment yet
start to write first comment